FDA Expands Durvalumab Label to Operable Lung Cancer

Published Date: 19 Aug 2024

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

2.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

3.

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

4.

AI tool automates liver tumor detection and monitoring

5.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot